Artículos del autor

solaci

Coronary disease

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat...
solaci -
Institutional News

SOLACI-CACI 2021 Webinar | Challenges in TAVI – Severe CAD & Coronary Occlusion

Next Thursday, October 14, we will hold a joint event between SOLACI, CACI and the Microport company...
solaci -
Structural heart disease

More Keys to Define Moderate Aortic Stenosis

Amidst the current efforts to prove early intervention might have benefits in moderate aortic stenosis (AS), this...
solaci -
Acute coronary syndromes

STOPDAPT-2 ACS: One-Month DAPT NOT Enough in acute patients

One-month dual antiplatelet therapy (DAPT) in patients undergoing acute coronary syndrome (ACS) did not reach the safety...
solaci -
Structural heart disease

The FDA Approves a Third Device in the TAVR Race

The Portico self-expanding graft has obtained FDA approval and can now compete as one of the three...
solaci -
Institutional News

Watch Again Advanced Strategias on Bifurcations Management in our Youtube Account

Watch Again "Advanced Strategias on Bifurcations Management" in our Youtube Account Program Provisional stent technique as a treatment philosophy:...
solaci -
Institutional News

The latest scientific articles on TAVI published on our website

01- TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors? In some patients, using an anticoagulant agent is not...
solaci -
Institutional News

The most read scientific papers of September in interventional cardiology

01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early...
solaci -